We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“reinforce previous reports indicating that the advantage of TAVR over SAVR is not constant over time and might disappear or be reversed with longer follow-up.”
“HR for death or disabling stroke and all-cause mortality in the PARTNER 3 trial increased from 0.34 (95% CI: 0.12-0.97) and 0.41 (95% CI: 0.14-1.17) at 1 year to 1.17 (95% CI: 0.78-1.75) and 1.23 (95% CI: 0.79-1.90), respectively, at 5 years (P value for heterogeneity 0.03 for former and 0.06 for latter), suggesting a “catch-up” with TAVI.”
No takes yet. Share an insight, caveat, or question.
Sanjay Kaul (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: